BONE, published by Elsevier Science Inc, is a leading peer-reviewed journal that has established itself as a pivotal resource in the fields of Endocrinology, Diabetes and Metabolism, Histology, and Physiology. Since its inception in 1985 and continuing to 2025, this journal has consistently provided high-quality research, evidenced by its impressive Q1 category rankings and strong performance in Scopus metrics—ranking #7 in Histology and achieving notable percentiles in related fields. With a commitment to advancing knowledge and understanding in bone biology and associated pathological conditions, BONE serves as an essential platform for researchers and professionals aiming to contribute to the discourse in skeletal health and disease. While it is not an open-access publication, the journal ensures a broad dissemination of pivotal research findings, making it a critical asset for academics and practitioners devoted to fostering advancements in medical sciences.

Aging Clinical and Experimental Research, published by Springer, is a premier journal dedicated to advancing the field of geriatric medicine and understanding the complexities of aging. With a commitment to publishing high-quality original research, review articles, and clinical studies, this journal plays a crucial role in disseminating knowledge to researchers, healthcare professionals, and students interested in the biological, clinical, and social aspects of aging. Boasting a 2023 impact factor that places it in the Q2 quartile for both Aging and Geriatrics and Gerontology categories, it ranks favorably within the Scopus metrics—20th out of 116 in Geriatrics and Gerontology and 15th out of 38 in Aging. The journal provides vital insights for the ongoing discourse in aging research, making it an essential resource for those seeking to enhance their understanding of aging-related phenomena and improve healthcare outcomes across populations. The converged years of publication from 1989 to 2024 demonstrate its longstanding commitment to the field, highlighted by its notable presence in Germany and access to a broad international readership.

Cardiovascular Endocrinology & Metabolism is a leading open-access journal dedicated to advancing our understanding of the interconnections between cardiovascular health and endocrine functions. Published by Lippincott Williams & Wilkins, this journal serves as a vital resource for researchers and clinicians alike, providing timely insights into the intricate relationships between metabolic disorders and cardiovascular diseases. With an impressive impact factor and categorized in Q2 for both Cardiology and Cardiovascular Medicine as well as Endocrinology, Diabetes, and Metabolism, it holds a significant position within its respective fields. The journal has been fully open access since its inception in 2012, ensuring that critical research is accessible to a global audience. By fostering innovation and collaboration, Cardiovascular Endocrinology & Metabolism aims to promote better health outcomes and stimulate novel research directions, making it an essential resource for professionals striving to bridge the gaps between these two critical domains.

REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, published by Springer, is a leading journal in the field of endocrinology, diabetes, and metabolism, with an impressive Q1 ranking in both categories as of 2023. With an ISSN of 1389-9155 and E-ISSN 1573-2606, this journal serves as a vital resource for researchers, clinicians, and students seeking comprehensive reviews that address the latest advancements and interdisciplinary approaches in the management of endocrine and metabolic disorders. Operating from the Netherlands, it features articles that are rigorously peer-reviewed and is notable for its significant impact factor reflected in its Scopus rankings, placing it in the top percentile of its categories. Although it does not currently offer open access, it provides critical insights applicable to both basic and clinical settings, making it indispensable for those dedicated to enhancing patient outcomes in endocrine health.

Revista de Osteoporosis y Metabolismo Mineral, an esteemed journal published by the SOC ESPANOLA INVESTIGACION OSEA & METABOLISMO MINERAL, stands at the forefront of research in the fields of osteoporosis and mineral metabolism. Established in Spain, this Open Access journal has been providing a platform for the dissemination of innovative research and insights since 2009, ensuring accessibility for all stakeholders in the field. Although currently categorized in the Q4 quartile for Endocrinology, Diabetes and Metabolism (2023), it serves a vital role in fostering academic discourse and collaboration among researchers and healthcare professionals. With its ISSN 1889-836X and E-ISSN 2173-2345, the journal aims to contribute significantly to advancing knowledge and understanding in osteoporosis and associated metabolic disorders. The HIndex is currently not reported, highlighting the journal's emerging impact and potential for growth in the scientific community. Spanning a decade, from 2014 to 2024, the journal’s focus is an invaluable asset for students and professionals seeking to stay informed and engaged in this vital area of medicine.

Current Osteoporosis Reports, published by Springer, is a premier journal dedicated to advancing the understanding of osteoporosis and related metabolic bone diseases. With its ISSN 1544-1873 and E-ISSN 1544-2241, this esteemed publication has established itself as a vital resource in the field of endocrinology, diabetes, and metabolism, evidenced by its Q1 ranking and 82nd percentile in Scopus. Spanning from 2003 to 2024, the journal seeks to disseminate high-quality research, critical reviews, and comprehensive reports that address the complexities of osteoporosis, offering insights into diagnosis, treatment, and prevention strategies. Although not an open-access journal, Current Osteoporosis Reports ensures that researchers, healthcare professionals, and students have access to cutting-edge scientific knowledge that fuels innovative approaches to improving patient care and outcomes. The journal's impact in shaping the dialogue and research landscape in its domain underscores its importance for anyone invested in improving bone health.

Osteoporosis and Sarcopenia is a leading journal dedicated to the multidisciplinary exploration of diseases related to bone health and muscle degeneration, published by Elsevier. With an ISSN of 2405-5255 and an E-ISSN of 2405-5263, this open-access journal has been a vital resource since its inception in 2015, enabling unrestricted access to groundbreaking research. Its objective is to elucidate the interplay between osteoporosis and sarcopenia, offering valuable insights into diagnostics, treatment strategies, and preventive measures in the field. The journal serves as a crucial platform for researchers, healthcare professionals, and students, fostering collaboration and innovation in understanding these prevalent conditions. Given the global rise in aging populations, the significance of this journal cannot be overstated, making it an essential reference for those committed to advancing knowledge in musculoskeletal health.

JOURNAL OF CLINICAL DENSITOMETRY, published by ELSEVIER SCIENCE INC, stands as a pivotal platform for the dissemination of cutting-edge research in the fields of endocrinology, orthopedics, and radiology. With an ISSN of 1094-6950 and an E-ISSN of 1559-0747, this journal supports the academic community with vital insights and advancements in clinical densitometry since its inception in 1998. The journal is recognized within the medical community, boasting impressive rankings such as Q3 in Endocrinology, Diabetes, and Metabolism, and Q2 in both Orthopedics and Sports Medicine and Radiology, Nuclear Medicine, and Imaging for 2023. These accolades underscore its significance as a valuable resource for researchers, healthcare professionals, and students aiming to advance their knowledge and practice in these critical areas. While it is not an Open Access publication, the journal provides vital contributions to the literature, emphasizing the importance of evidence-based approaches in clinical settings.

Journal of Bone Oncology, published by ELSEVIER, is a pivotal open access journal that has been advancing the field of oncology since its inception in 2012. Focused on the intricate relationship between bone-related malignancies and therapeutic advancements, this journal addresses critical issues in bone oncology, including novel treatments, diagnostic methodologies, and translational research. With a commendable impact factor reflecting its scholarly contributions and ranking in the Q2 category of oncology journals (2023), the Journal of Bone Oncology is recognized within the top 67th percentile across Scopus rankings, showcasing its relevance and quality in the medical oncology landscape. Available in open access, the journal promotes widespread dissemination of knowledge, ensuring that researchers, professionals, and students can access groundbreaking research that informs clinical practices and enhances patient outcomes. Located in Germany and targeting a global audience, the journal’s wealth of resources serves as an essential platform for fostering collaboration and innovation in the oncology community.

JOURNAL OF SUBSTANCE ABUSE TREATMENT, published by Pergamon-Elsevier Science Ltd, is a leading peer-reviewed journal that spans a wide range of topics related to substance abuse and addiction treatments. With an impressive impact factor, this esteemed journal ranks in the Q1 quartile across multiple disciplines including Clinical Psychology, Medicine (miscellaneous), and Psychiatry and Mental Health, making it a vital resource for researchers and practitioners alike. Covering convergence years from 1984 to 2023, it publishes cutting-edge research that informs treatment methodologies and policy development in the field of substance abuse. With access options that adapt to both traditional and modern academic needs, the journal seeks to advance the understanding and effectiveness of substance abuse treatment through comprehensive studies and innovative approaches. Be part of a global dialogue that shapes the future of addiction treatment by engaging with the latest findings and expert analyses that help bridge the gap between research and clinical practice.